Meeting
2023 ASCO Breakthrough
Preclinical evaluation of JAK2 specific investigational oligonucleotide for the treatment of MDS/PV.
Authors
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc., Washington, DC
Bartlomiej Przychodzen , Sandra Paulina Smieszek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Targeted Therapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 122)
DOI
10.1200/GO.2023.9.Supplement_1.122
Abstract #
122
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).
First Author: Francesco Passamonti
Poster
2013 Breast Cancer Symposium
Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).
First Author: Eleonora Teplinsky
First Author: Dmitriy Sonkin
Poster
2011 ASCO Annual Meeting
RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
First Author: S. Verstovsek